Resverlogix Corp. (RVXCF)
- Previous Close
0.0416 - Open
0.0416 - Bid --
- Ask --
- Day's Range
0.0416 - 0.0416 - 52 Week Range
0.0300 - 0.1100 - Volume
100 - Avg. Volume
8,817 - Market Cap (intraday)
12.056M - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.
www.resverlogix.comRecent News: RVXCF
Performance Overview: RVXCF
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RVXCF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RVXCF
Valuation Measures
Market Cap
11.05M
Enterprise Value
17.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.26
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.23%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-16.74M
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
5k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
2.75M
Research Analysis: RVXCF
Company Insights: RVXCF
RVXCF does not have Company Insights